Skip to main content
. 2022 Sep 25;12(16):6848–6864. doi: 10.7150/thno.73078

Figure 5.

Figure 5

Validation of LVX/RFB drug interaction space. (A) Response surface of LVX/RFB in the validation interaction space (0% - 20% Cmax). All replicates (N = 3) were included for the construction of the response surface. The clinically actionable interaction space (< 10% Cmax) is within the dotted black box. The adjusted R2 indicates the goodness of the fit for the response surface. (B) Clinically actionable interaction space is the magnification of the dotted black box in Figure 5A. (C) The heatmap represents the 2-dimensional view of the LVX/RFB response surface in the validation interaction space (0% - 20% Cmax). The clinically actionable interaction space (< 10% Cmax) is within the dotted black box. Experimental data are summarized in Figure S5 and Table S7. Statistics for the response surface are detailed in Table S8. LVX: levofloxacin and RFB: rifabutin.